Inhibition of Sodium Glucose Cotransporter 2 Attenuates the Dysregulation of Kelch-Like 3 and NaCl Cotransporter in Obese Diabetic Mice.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
05 2019
Historique:
received: 10 07 2018
accepted: 08 02 2019
pubmed: 28 3 2019
medline: 28 2 2020
entrez: 28 3 2019
Statut: ppublish

Résumé

Mechanisms underlying the frequent association between salt-sensitive hypertension and type 2 diabetes remain obscure. We previously found that protein kinase C (PKC) activation phosphorylates Kelch-like 3 (KLHL3), an E3 ubiquitin ligase component, at serine 433. We investigated whether impaired KLHL3 activity results in increased renal salt reabsorption We used the db/db diabetes mouse model to explore KLHL3's role in renal salt handling in type 2 diabetes and evaluated mechanisms of KLHL3 dysregulation in cultured cells. We observed PKC activity in the db/db mouse kidney and phosphorylation of serine 433 in KLHL3 (KLHL3 Dysregulation of KLHL3 is involved in the pathophysiology of type 2 diabetes. These data offer a rationale for use of thiazide in individuals with diabetes and provide insights into the mechanism for cardiorenal protective effects of SGLT2 inhibitors.

Sections du résumé

BACKGROUND
Mechanisms underlying the frequent association between salt-sensitive hypertension and type 2 diabetes remain obscure. We previously found that protein kinase C (PKC) activation phosphorylates Kelch-like 3 (KLHL3), an E3 ubiquitin ligase component, at serine 433. We investigated whether impaired KLHL3 activity results in increased renal salt reabsorption
METHODS
We used the db/db diabetes mouse model to explore KLHL3's role in renal salt handling in type 2 diabetes and evaluated mechanisms of KLHL3 dysregulation in cultured cells.
RESULTS
We observed PKC activity in the db/db mouse kidney and phosphorylation of serine 433 in KLHL3 (KLHL3
CONCLUSIONS
Dysregulation of KLHL3 is involved in the pathophysiology of type 2 diabetes. These data offer a rationale for use of thiazide in individuals with diabetes and provide insights into the mechanism for cardiorenal protective effects of SGLT2 inhibitors.

Identifiants

pubmed: 30914436
pii: ASN.2018070703
doi: 10.1681/ASN.2018070703
pmc: PMC6493993
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Carrier Proteins 0
Glucosides 0
KLHL3 protein, mouse 0
Microfilament Proteins 0
Sodium-Glucose Transporter 2 Inhibitors 0
Solute Carrier Family 12, Member 3 0
Thiophenes 0
ipragliflozin 3N2N8OOR7X
WNK Lysine-Deficient Protein Kinase 1 EC 2.7.11.1
Protein Kinase C EC 2.7.11.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

782-794

Informations de copyright

Copyright © 2019 by the American Society of Nephrology.

Références

Metabolism. 2001 Nov;50(11):1294-300
pubmed: 11699047
Hypertension. 2001 Apr;37(4):1053-9
pubmed: 11304502
BMJ. 1992 May 2;304(6835):1157
pubmed: 1392796
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E879-E886
pubmed: 28096417
Diabetes. 2013 Apr;62(4):1167-74
pubmed: 23434935
J Am Soc Nephrol. 2014 Mar;25(3):511-22
pubmed: 24231659
J Clin Invest. 2014 Nov;124(11):4723-36
pubmed: 25250572
Nature. 2012 Jan 22;482(7383):98-102
pubmed: 22266938
J Clin Invest. 1976 Jul;58(1):83-90
pubmed: 932211
Hypertension. 2007 Dec;50(6):1099-105
pubmed: 17968000
Diabetes. 1996 Apr;45(4):522-30
pubmed: 8603776
Am J Physiol Renal Physiol. 2011 Apr;300(4):F957-65
pubmed: 21228110
Diabetes. 2006 Jun;55(6):1832-9
pubmed: 16731850
Biochem Biophys Res Commun. 2017 May 27;487(2):368-374
pubmed: 28414128
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15556-61
pubmed: 25313067
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Hypertension. 1990 Jun;15(6 Pt 1):547-59
pubmed: 1971810
Curr Opin Nephrol Hypertens. 2004 Jan;13(1):107-15
pubmed: 15090867
J Am Soc Nephrol. 2001 Mar;12(3):431-9
pubmed: 11181790
J Am Soc Nephrol. 2015 Oct;26(10):2388-97
pubmed: 25653098
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4384-9
pubmed: 19240212
Clin Sci (Lond). 2012 Dec;123(11):635-47
pubmed: 22651238
J Am Soc Hypertens. 2008 Sep-Oct;2(5):332-40
pubmed: 20409915
Nephrol Dial Transplant. 2016 Sep;31(9):1417-24
pubmed: 26152401
Sci Signal. 2014 May 06;7(324):ra41
pubmed: 24803536
JAMA. 2002 Nov 27;288(20):2579-88
pubmed: 12444865
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Am J Physiol Regul Integr Comp Physiol. 2012 Dec;303(11):R1101-9
pubmed: 23034715
Biochem J. 2005 Oct 1;391(Pt 1):17-24
pubmed: 16083423
Science. 2001 Aug 10;293(5532):1107-12
pubmed: 11498583
Am J Physiol. 1991 May;260(5 Pt 2):F663-9
pubmed: 2035653
Hypertension. 2012 Oct;60(4):981-90
pubmed: 22949526
J Clin Invest. 2011 May;121(5):2037-47
pubmed: 21505260
Nature. 2001 Dec 13;414(6865):813-20
pubmed: 11742414
Biochem J. 2013 Apr 1;451(1):111-22
pubmed: 23387299
Hypertension. 2014 Apr;63(4):774-82
pubmed: 24446061
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Nat Med. 2008 Dec;14(12):1370-6
pubmed: 19029984
J Clin Invest. 2015 Sep;125(9):3433-48
pubmed: 26241057
Cell Rep. 2013 Mar 28;3(3):858-68
pubmed: 23453970
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
J Cell Sci. 2008 Mar 1;121(Pt 5):675-84
pubmed: 18270262
Hypertension. 1985 Nov-Dec;7(6 Pt 2):II3-7
pubmed: 4077239
Cell Metab. 2013 Nov 5;18(5):660-71
pubmed: 24206662
J Clin Invest. 1990 Mar;85(3):962-7
pubmed: 2312736
J Am Soc Nephrol. 2015 Aug;26(8):1781-6
pubmed: 25542968
Biochem Biophys Res Commun. 2016 Nov;480(4):745-751
pubmed: 27942049
Hypertension. 2017 May;69(5):855-862
pubmed: 28289181
Diabetes. 1992 Nov;41(11):1464-72
pubmed: 1397722
Nat Genet. 2012 Mar 11;44(4):456-60, S1-3
pubmed: 22406640
J Hypertens. 1990 May;8(5):479-82
pubmed: 2163424
Cell Metab. 2015 Jan 6;21(1):39-50
pubmed: 25565204
PLoS One. 2017 Oct 20;12(10):e0185600
pubmed: 29053707
Am J Physiol Renal Physiol. 2002 Jul;283(1):F29-40
pubmed: 12060584
Am J Physiol Renal Physiol. 2006 May;290(5):F1055-64
pubmed: 16303859
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7838-43
pubmed: 23576762
J Am Soc Nephrol. 2015 Nov;26(11):2669-77
pubmed: 25817355

Auteurs

Kenichi Ishizawa (K)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Qin Wang (Q)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Department of Nephrology, Second Affiliated Hospital of Harbin Medical University, Harbin, China; and.

Jinping Li (J)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Ning Xu (N)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Yoshikazu Nemoto (Y)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Chikayuki Morimoto (C)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Wataru Fujii (W)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Yoshifuru Tamura (Y)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Yoshihide Fujigaki (Y)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Kazuhisa Tsukamoto (K)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Toshiro Fujita (T)

Division of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Shunya Uchida (S)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Shigeru Shibata (S)

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan; shigeru.shibata@med.teikyo-u.ac.jp.
Division of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH